Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says
News
An independent data monitoring committee (DMC) has deemed it unlikely that a combination of endocrine therapy and Pfizer’s Ibrance (palbociclib) will show benefits over standard therapy at delaying or preventing ... Read more